IMNM - Immunome Inc Debt to Book Capitalization Ratio
Immunome, Inc. (IMNM) price action reflects a current level of 0.01. The business leverages advanced AI technologies to discover antibodies for combating tumors. The company's stability is underpinned by US laboratories and successful immune response tests. Currently, Immunome, Inc. (IMNM) is actively acquiring promising molecules through M&A transactions to accelerate the renewal of its drug portfolio.
%20Debt%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_IMNM_-_Immunome-Inc._-_Debt-to-Net-Assets-Ratio "Immunome, Inc. - IMNM Debt to Book Capitalization Ratio (period 07/04/2022 - 10/28/2026) | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Immunome Inc (IMNM)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Summary company analytics:Immunome, Inc. (IMNM)
This indicator measures the debt load level by comparing total liabilities to equity to assess financial stability and default risks. By analyzing the total debt-to-equity ratio, an investor can determine the margin of safety for Immunome, Inc. (IMNM), which is critical when financing the costly development of antibodies and ADC drugs prior to their full market launch.
Who Immunome, Inc. competes with
Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Debts to Book Capitalization GOSS (Gossamer Corp)|KALV: Debts to Net Assets|SEPN (Septerna Inc) - Debt to Book Capitalization Ratio|PVLA (pieris.com) - Debt to Book Value|Debt to Book Capitalization Ratio SVRA|Debt to Book Value Rigel Pharma (RIGL)|Debt to Book Value ANAB|Debts to Book Capitalization ATXS (Astria Corp)|ENGN - Debt to Book Capitalization Ratio|RAPT Therapeutics Inc. - Debt to Book Value Ratio|JBIO (Aerovate) - Debt to Book Capitalization Ratio|ACRS: Debts to Book Value|KYTX (Kyverna) - Debt to Book Capitalization Ratio|Tiziana Life Sciences, Ltd. (TLSA) - Debt to Book Value|Debts to Book Capitalization CABA (Cabaletta Bio, Inc.)|Debts to Book Value ventyxbio.com (VTYX)|Theratechnologies (THTX) - Debt to Book Value|Debt to Net Assets Ratio Avalo Therapeutics, Inc. (AVTX)|Debts to Book Capitalization ELDN|Agenus, Inc - Debts to Net Assets|Climb Bio Inc (CLYM) - Debt to Book Capitalization Ratio|ZURA - Debt to Book Value Ratio|ATYR (aTyr Pharma) - Debts to Book Capitalization|Debt to Book Value Adagene Inc.|IMA: Debt to Book Value|Debts to Net Assets Shattuck Therapeutics|EQ (Equillium, Inc.) - Debts to Book Capitalization|Debts to Net Assets CNTB (connectbiopharm.com)|Immunic - Debt to Book Capitalization Ratio|Atara Biotherapeutics, Inc. - Debt to Book Value|InflaRx GmbH (IFRX) - Debt to Book Capitalization Ratio|XFOR: Debt to Book Value Ratio|ACET (adicetbio.com) - Debt to Book Capitalization Ratio|CELU (Celularity) - Debt to Book Value|Debt to Book Capitalization Ratio INmune Bio INMB|Debts to Book Capitalization Ratio Barinthus Biotherapeutics PLC|Kezar Life Sciences, Inc (KZR) - Debts to Book Capitalization|Debt to Net Assets Ratio SAB Biotherapeutics Inc (SABS)|Debts to Book Capitalization AKTX (Akari Therapeutics)|Enlivex Therapeutics Ltd - Debts to Book Capitalization|Debt to Book Capitalization Ratio Q32 Bio Corp (QTTB)|GOVX: Debt to Net Assets Ratio|EDSA (Edesa) - Debt to Book Capitalization Ratio|iBio Corporation (IBIO) - Debt to Book Value|CARM (Carisma Therapeutics Inc) - Debts to Book Capitalization|Debts to Book Capitalization xtlbio.com (XTLB)|Bolt Biotherapeutics (BOLT) - Debt to Book Value|Debt to Net Assets Ratio hcwbiologics.com (HCWB)|Debts to Book Capitalization APVO|AIM ImmunoTech, Inc. - Debts to Net Assets|ADTX: Debt to Book Capitalization Ratio|GRI: Debt to Book Value|XRTX (XORTX Therapeutics) - Debt to Book Capitalization Ratio|Debt to Book Value Vyome Holdings Inc.|REVB (Revelation Bio) - Debt to Book Value|Debts to Book Capitalization INDP|Debt to Book Capitalization Ratio Scinai Immunotherapeutics SCNI|Debt to Book Value Ratio calcimedica.com (CALI)|AFMD: Debts to Book Capitalization|Debts to Book Value Allakos Inc ALLK|Debts to Book Capitalization HOOK (HOOKIPA)|IGMS: Debts to Net Assets|ITOS (iTeos Therapeutics) - Debt to Book Capitalization Ratio|OCEA (oceanbiomedical.com) - Debt to Book Value|Debt to Book Capitalization Ratio TCBP|Debt to Book Value Third Harmonic Bio Inc. (THRD)